...
首页> 外文期刊>Allergy >Specific immimotherapy - an optimistic future
【24h】

Specific immimotherapy - an optimistic future

机译:特定的免疫疗法-乐观的未来

获取原文
获取原文并翻译 | 示例
           

摘要

Allergen-specific immunotherapy (SIT) for the treatment of allergic rhinitis and asthma was first introduced in 1911. Although millions of patients have received this form of treatment, it has remained a controversial therapy since its inception. The vast majority of randomized, double-blind, placebo-controlled trials have been performed since the 1960s and standardized allergen vaccines have only been available for the past 25 years (1)
机译:1911年首次引入了用于治疗变应性鼻炎和哮喘的变应原特异性免疫疗法(SIT)。尽管成千上万的患者接受了这种形式的治疗,但自开始以来一直是有争议的疗法。自1960年代以来,已进行了绝大多数的随机,双盲,安慰剂对照试验,而标准化的过敏原疫苗仅在过去25年内可用(1)

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号